Michael Andrew Chambers - 14 Sep 2022 Form 4 Insider Report for Sarepta Therapeutics, Inc. (SRPT)

Role
Director
Signature
/s/ Ryan Brown, as Attorney-in-Fact for Michael Andrew Chambers
Issuer symbol
SRPT
Transactions as of
14 Sep 2022
Transactions value $
$5,963,124
Form type
4
Filing time
15 Sep 2022, 08:00:25 UTC
Previous filing
14 Sep 2022
Next filing
08 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SRPT Common Stock Purchase $2.15M +20.7K +40.61% $103.87 71.8K 14 Sep 2022 Direct F1
transaction SRPT Common Stock Purchase $3.15M +30.1K +41.92% $104.67 102K 14 Sep 2022 Direct F2
transaction SRPT Common Stock Purchase $657K +6.25K +6.13% $105.16 108K 14 Sep 2022 Direct F3
holding SRPT Common Stock 75.2K 14 Sep 2022 By Revocable Trust
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $103.06 to $104.05, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
F2 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $104.065 to $105.05, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.
F3 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $105.085 to $105.40, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth above.